Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir
Yu Bai, Fei Ye, Yong Feng, Hanyi Liao, Hao Song, Jianxun Qi, George F. Gao, Wenjie Tan, Lifeng Fu, Yi Xiang Shi · Signal Transduction and Targeted Therapy · 2021
The second wave of the coronavirus disease (COVID-19) pandemic has recently appeared in Europe. Most European countries, such as France, Germany, and Italy, have announced the implementation of a new round of epidemic prevention and control measures. However, no clinical drug or vaccine has been approved for the treatment of COVID-19. The interim results of the solidarity therapy trial coordinated by the World Health Organization (WHO) indicated that remdesivir, hydroxychloroquine, lopinavir/ritonavir, and interferon appear to have little or no effect on the 28-day mortality of hospitalized patients or the hospitalization process of new COVID-19 patients. Therefore, there is an urgent need to develop new drugs against COVID-19.